Novo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis
The post hoc analysis of the REDEFINE 1 trial found average losses of 23.1% to 26.7% across menopause stages
We haven't written up this one. Quartz has the full story — the link below goes straight to it.